Received Jan 21, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 1 | — | — |
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 2 | — | — |
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 3 | — | — |
No additional AE reported; an adult patient was at the facility for their first dose on 28JUL2025, their second dose on 04SEP2025, and that they were at the facility today, 15JAN2026, for their third dose.; This spontaneous report was received from a Physician Assistant and refers to an Adult patient of unknown gender. The patient's medical history, concurrent conditions, and concomitant therapies were not reported. On 28-Jul-2025, the patient was vaccinated with Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB), Suspension for injection, dose number 1, (lot # and expiration date were not reported) for prophylaxis. On 04-Sep-2025, the patient was vaccinated with Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB), Suspension for injection, dose number 2, (lot # and expiration date were not reported) for prophylaxis. On 15-Jan-2026, the patient was vaccinated with Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB), Suspension for injection, dose number 3, (lot # and expiration date were not reported) for prophylaxis (Inappropriate schedule of product administration). No additional AE reported (no adverse event). Lot # is being requested and will be submitted if received.